profit from every $100 of sales.
$0$100
Oculis
$7.64+1.87% today
-60.4% in 1 year
1-year low $6.831-year high $32.65
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Oculis sold, what it kept, and what it did with the cash.
Sales went from CHF 0 in 2022 to CHF 0 in 2025, with -CHF 99.0 million of profit last year.
SalesProfit
Oculis vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Oculis | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Oculis's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -32 | -46 | -73 | -82 | |
| -32 | -87 | -85 | -98 | |
| -39 | -89 | -86 | -99 | |
| -11.32 | -2.97 | -2.12 | -1.89 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 37 | 114 | 120 | 236 |
| Cash | 20 | 38 | 28 | 81 |
| Total debt | 1 | 1 | 1 | 2 |
| Total liabilities | 135 | 21 | 47 | 40 |
| -98 | 94 | 73 | 196 | |
| 33 | 30 | 40 | 52 | |
| – | -73.2% | -90.4% | -39.1% | |
| 39.5% | -94.7% | -116.9% | -50.5% |
Cash flow
| In millions of CHF | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -25 | -55 | -49 | -66 | |
| 4 | 0 | 0 | 1 | |
| -29 | -55 | -49 | -68 | |
| Dividends paid | – | 0 | 0 | 0 |
| – | – | – | – | |
| 1 | 4 | 10 | 16 |
Valuation
- –
- –
- –
- 7.2×
- –
- –
- –
- -22.3%
- -33.7%
- 0.0%
Profitability
- -2,889.4%
- -16,741.0%
- -18,861.3%
- -16,814.2%
- -42.1%
- -89.2%
- -57.1%
- -39.1%
- -42.3%
- 11,206.4%
Growth
- –
- –
- −31.0%
- –
- +12.5%
Financial health
- 0.7×
- 0.01
- 0.9%
- -105.3×
- 5.18
- 5.18
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 9%of 952
Bottom 3%of 987
What analysts expect
- Average price target
- $50.00
- Range
- $50.00 – $50.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 11, 2026 | -0.63 | -0.49 | −28.6% |
| Mar 3, 2026 | -0.51 | -0.48 | −6.7% |
| Nov 10, 2025 | -0.40 | -0.50 | +20.0% |
| Aug 21, 2025 | -0.59 | -0.53 | −11.3% |
| May 8, 2025 | -0.77 | -0.51 | −51.0% |
| Mar 11, 2025 | -0.76 | -0.48 | −58.3% |
| Nov 7, 2024 | -0.55 | -0.52 | −5.8% |
| Aug 27, 2024 | -0.56 | -0.43 | −30.2% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
25No pass
Benjamin Graham
40No pass
Philip Fisher
30No pass
Peter Lynch
–Not enough data
Joel Greenblatt
0No pass
Charlie Munger
36No pass
Terry Smith
30No pass
Questions about Oculis
Is Oculis a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Oculis AI analysis
What does Oculis do?
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. It is in Biotechnology.
Does Oculis pay a dividend?
No. Oculis does not pay a dividend at the moment.
Is Oculis stock halal?
Questionable. Oculis sits in a grey zone: short-term investments may earn interest; type not reported. How we check
How has Oculis stock done over the past year?
Down 60.4% over the past twelve months, to $7.64. It traded between $6.83 and $32.65 and is 76.6% below its high.
Who are Oculis's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Oculis's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.